Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease

Phase 3BuntanetapPositive

AI Analysis

Summary

Annovis Bio has completed patient enrollment for its Phase 3 study of Buntanetap in Alzheimer's Disease. The completion of enrollment is a key milestone that brings the program closer to data readout.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Patient enrollment completed

Importance:6/10

Sentiment:

0.60

Phase 3Alzheimer's DiseasePatient EnrollmentBuntanetap

Related Companies

$ANVS

Read the original article

Published by yahoo_finance on July 7, 2026 11:18 AM

Read Original